



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
 International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C12N 5/00, 5/02, A01N 63/00, 1/02</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/27997 (43) International Publication Date: 18 May 2000 (18.05.00)</p>
<p>(21) International Application Number: PCT/US99/26240 (22) International Filing Date: 8 November 1999 (08.11.99) (30) Priority Data: P98 01 05611 6 November 1998 (06.11.98) AR P99 01 00681 23 February 1999 (23.02.99) AR (71) Applicant (for all designated States except US): STERREN-BELD BIOTECHNOLOGIE NORTH AMERICA, INC. [US/US]; 1209 Orange Street, Wilmington, DE 19801 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CARCAGNO, Carlos, Miguel [AR/AR]; Guevara 275, 1427 Buenos Aires (AR). CRISCUOLO, Marcelo [AR/AR]; Guevara 349, 1427 Buenos Aires (AR). MELO, Carlos [AR/AR]; Alsina 2737, Del Viso, Pcia Buenos Aires 1669 (AR). VIDAL, Juan, Alejandro [AR/AR]; 9th floor, Apartment A, Guise 1760, 1425 Buenos Aires (AR). (74) Agents: GOLDSTEIN, Jorge, A. et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: METHOD FOR THE MASSIVE CULTURE OF CELLS PRODUCING RECOMBINANT HUMAN ERYTHROPOIETIN (57) Abstract The present invention relates, in general, to a method for the massive culture of recombinant mammalian cells for the production of recombinant human erythropoietin (EPO) in culture medium containing insulin. The present invention also refers to a method of producing EPO and to the EPO thus produced.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Method for the Massive Culture of Cells Producing Recombinant Human Erythropoietin

Background of the Invention

Field of the Invention

5 The present invention relates, in general, to a method for the massive culture of recombinant mammalian cells for the production of recombinant human erythropoietin (EPO) in a culture medium containing insulin. The present invention also refers to a method of producing EPO and to the EPO thus produced.

10 ***Background Information***

 EPO is a glycoprotein that stimulates erythroblast differentiation in the bone marrow, thus increasing the circulating blood erythrocyte count. The mean life of erythrocytes in humans is 120 days and therefore, a human being loses 1/120 erythrocytes each day. This loss must be continuously restored to maintain
15 an adequate level of red blood cells.

 The existence of EPO was first postulated by the turn of the century and was definitely proved by Reissman and Erslev early in the '50s. See Carnot, et al., *C.R. Acad. Sci. (France)*, 143, 384-6 (1906); Carnot, et al., *C.R. Acad. Sci. (France)*, 143, 432-5 (1906); Carnot, et al., *C.R. Soc. Biol.*, 111, 344-6 (1906);
20 Carnot, *C.R. Soc. Biol.*, 111, 463-5 (1906); Reissman, *Blood*, 1950, 5, 372-80 (1950) and Erslev, *Blood*, 8, 349-57 (1953). Reissman and Erslev's experiments were promptly confirmed by other researchers. See Hodgson, et al., *Blood*, 9, 299-309 (1954); Gordon, et al., *Proc. Soc. Exp. Biol. Med.*, 86, 255-8 (1954) and Borsook, et al., *Blood*, 9, 734-42 (1954).

25 The identification of the EPO production site in the organism was an issue of debate. Successive experiments led to identify the kidney as the main organ and peritubular interstitial cells as the synthesis site. See Jacobson, et al., *Nature*, 179, 633-4 (1957); Kuratowska, et al., *Blood*, 18, 527-34 (1961); Fisher, *Acta*

Hematol., 26, 224-32 (1961); Fisher, et al., *Nature*, 205, 611-2 (1965); Frenkel, et al., *Ann. N.Y. Acad. Sci.*, 149, 1, 292-3 (1968); Busuttil, et al., *Proc. Soc. Exp. Biol. Med.*, 137, 1, 327-30 (1971); Busuttil, *Acta Haematol.*, (Switzerland), 47, 4, 238-42 (1972); Erslev, *Blood*, 44, 1, 77-85 (1974); Kazal, *Ann. Clin. Lab. Sci.*, 5, 2, 98-109 (1975); Sherwood, et al., *Endocrinology*, 99, 2, 504-10 (1976); Fisher, *Ann. Rev. Pharmacol. Toxicol.*, 28, 101-22 (1988); Jelkmann, et al., *Exp. Hematol.*, 11, 7, 581-8 (1983); Kurtz, et al., *Proc. Natl. Acad. Sci. (USA)*, 80, 13, 4008-11 (1983); Caro, et al., *J. Lab. Clin. Med.*, 103, 6, 922-31 (1984); Caro, et al., *Exp. Hematol.*, 12, 357 (1984); Schuster, et al., *Blood*, 70, 1, 316-8 (1986); Bondurant, et al., *Mol. Cell. Biol.*, 6, 7, 2731-3 (1986); Bondurant, et al., *Mol. Cell. Biol.*, 6, 7, 2731-3 (1986); Schuster, et al., *Blood*, 71, 2, 524-7 (1988); Koury, et al., *Blood*, 71, 2, 524-7 (1988); Lacombe, et al., *J. Clin. Invest.*, 81, 2, 620-3 (1988); Koury, et al., *Blood*, 74, 2, 645-51 (1989).

A smaller proportion, ranging from 10% to 15% of total EPO, is produced by the liver in adults. See Naughton, et al., *J. Surg. Oncol.*, 12, 3, 227-42 (1979); Liu, et al., *J. Surg. Oncol.*, 15, 2, 121-32 (1980); Dornfest, et al., *Ann. Clin. Lab. Sci.*, 11, 1, 37-46 (1981); Dinkelaar, et al., *Exp. Hematol.*, 9, 7, 796-803 (1981); Caro, et al., *Am. J. Physiol.*, 244, 5 (1983); Dornfest, et al., *J. Lab. Clin. Med.*, 102, 2, 274-85 (1983); Naughton, et al., *Ann. Clin. Lab. Sci.*, 13, 5, 432-8 (1983); Jacobs, et al., *Nature*, 313, 6005, 806-10 (1985); Erslev, et al., *Med. Oncol. Tumor. Pharmacother.*, 3, 3-4, 159-64 (1986). The EPO produced is directly proportional to the extent of tissular hypoxia and its expression rises by increasing the number of the EPO producing cells.

EPO has shown great efficiency in the treatment of anemia, especially anemia derived from renal failure. See Eschbach, et al., *N. England J. of Med.*, 316, 2, 73-78 (1987); Krane, *Henry Ford Hosp. Med. J.*, 31, 3, 177-181 (1983). Its therapeutical usefulness, however, has been limited due to the unavailability of a massive production method. The quantity and quality of the EPO obtained by the extractive systems known were insufficient. Recently, the use of recombinant DNA technology has made it possible to obtain large amounts of proteins. The application of these techniques to eukaryotic cells has allowed a

large scale production of EPO. See patents US 5,688,679 (to Powell), US 5,547,933 (to Lin), US 5,756,349 (to Lin), US 4,703,008 (to Lin) and US 4,677,195 (to Hewick et al.)

5 Notwithstanding the recent considerable literature referring to the production of EPO in mammalian cell cultures, no method has yet been devised to produce efficiently EPO in industrial scale. The existent EPO culture systems are further characterized by their low reproducibility and output quality. See US 5,688,679 (to Powell); US 5,547,933 (to Lin); US 5,756,349 (to Lin); US 4,703,008 (to Lin) and US. 4,677,195 (to Hewick et al.); Andersen, et al., *Curr.*
10 *Op. Biotech*, 5,546-549 (1994); Butler, Ed., "Mammalian Cell Biotechnology", (IRL Press, Oxford, England, 1991); Murakami, Ed., "Trends in Animal Cell Culture Technology", (Kodansha Ltd., Tokyo, Japan, 1990); Freshney, Ed., "Animal Cell Culture. A Practical Approach," Ch. 3, (IRL Press, Oxford, England, 1986); Pirt, "Principles of Microbe and Cell Cultivation", (Blackwell
15 Scientific Pub., London, England, 1985); Hames et als., "Transcription and Translation. A Practical Approach", (IRL Press, Oxford, England, 1984).

Summary of the Invention

The present invention provides a method for obtaining human erythropoietin (EPO) comprising culturing mammalian cells which express
20 recombinant human erythropoietin in a culture medium comprising insulin.

The invention specifically relates to a method for obtaining human EPO that comprises the separation of a supernatant comprising EPO and insulin from cells which express recombinant human EPO, the concentration of said supernatant and the freezing of the resulting concentrated product.

25 The present invention describes a method for the massive culture of recombinant cells adequate for the industrial production of EPO. The method described in the present invention produces an unexpectedly high amount of EPO with a low concentration of contaminant proteins in the culture medium. This condition enhances the subsequent EPO purification steps and results in a high

protein recovery ratio. The high yield of EPO obtained by the claimed method is achieved by the addition of insulin to the culture medium.

Other advantages of the claimed method are: 1) its reproducibility and 2) the high quality of the EPO obtained regardless of the protein production scale.

5 The method claimed in the present invention utilizes EPO producing cells preserved in liquid nitrogen (Master and Working Bank). The cells are thawed and multiplied through successive expansion steps at 37 °C with different culture media. The expansion is sustained until a cellular mass adequate for industrial scale production is achieved. The cells are grown in T25 (25 cm² surface area)
10 flasks and transferred to flasks with increasing surface areas until a final roller flask surface of 850 cm² is reached. The culture medium employed for the cell expansion is then replaced by an improved culture medium containing insulin to enhance the production of EPO. After 72 hours, the EPO containing supernatant is first recovered, purified and assayed.

15 The obtained culture supernatant is assayed by SDS-PAGE, Western blot, glycanase treatment followed by SDS-PAGE, isoelectric focusing and a complete protein sequence analysis to verify the identity of the EPO produced. The *in vivo* biological activity of the EPO thus produced is determined by an ex-hypoxic polycythemic mice assay using the World Health Organization EPO standard as
20 reference.

Brief Description of the Figures

Fig. 1 illustrates a polyacrylamide gel electrophoresis (SDS-PAGE) assay performed on an EPO sample obtained according to the method herein described. Lanes 1, 4 and 7 show molecular weight markers. On lanes 2, 3, 5 and 6 different
25 pure EPO samples were run according to the claimed method. The purity of the obtained product, as well as its apparent molecular weight, somewhat superior to 30 kDa, is coincident with that of urinary human EPO.

Fig. 2 illustrates a "Western Blot" assay performed on an EPO sample obtained according to the method described herein. The produced EPO identity

is verified by the recognition of an antibody against human EPO. On lane 1 a human EPO standard sample was run; on lane 2 molecular weight markers were run and on lanes 3 to 5, EPO samples obtained according to the method claimed herein were run.

5 **Fig. 3** illustrates a SDS-PAGE assay performed on a pure EPO sample obtained according to the method described herein and submitted to glycanases treatment. Molecular weight markers were run on lanes 1, 4 and 8. Lanes 2 and 7 show untreated EPO samples. On lane 3 an EPO sample treated with O-glycanase was run, showing the existence of an O-glycosilation site. On lane 10 5 an EPO sample partially degraded with N-glycanase was run, verifying the presence of the molecular weight markers corresponding to those expected for EPO. On lane 6 an EPO sample degraded with O-glycanase and N-glycanase was run, showing the pattern expected for the fully deglycosilated protein.

15 **Fig. 4** illustrates an electrofocusing assay performed on pure EPO samples produced according to the method herein described. EPO samples were run on lanes 2, 3 and 4; isoelectric point markers were run on lanes 1 and 5. The presence of the EPO isoforms with isoelectric points ranging from 3.0 to 4.5 is observed.

Detailed Description of the Invention

20 The present invention provides a method for obtaining EPO comprising the culture of mammalian cells which express recombinant human erythropoietin in a substrate medium comprising insulin. The claimed invention is further characterized by the absence of fetal calf serum from the culture medium.

25 The EPO expressing cells in the present invention are selected from the group comprising mammalian cells. Preferably said mammalian cells are selected from the group comprising CHO, COS, BHK, Namalwa, and HeLa cells, and even more preferably said mammalian cells are CHO cells.

Preferred recombinant host cells comprise a vector which comprises a nucleotide sequence encoding the EPO polypeptide consisting of the amino acid

sequence in SEQ ID NO:1, a viral promoter and a viral terminator. Preferred host cell vectors confer resistance to both methotrexate and neomycin-derived antibiotics. Preferably, the EPO nucleic acid molecule comprises the nucleic acid molecule described in Lin, "DNA Sequences Encoding Erythropoietin," U.S. Patent No. 4,703,008. Preferably, the viral promoter is an SV40 early promoter.

The insulin in the culture medium in the above and below-described methods can be present in amounts from about 0.1 mg per liter of culture medium to about 40 mg per liter of culture media, and even more preferably from about 0.5 mg per liter of culture media to about 20 mg per liter of culture media.

In a further embodiment, the invention provides a method for obtaining human erythropoietin comprising the culture of mammalian cells which express recombinant human erythropoietin in culture media which comprises fetal calf serum-free media.

The invention also provides a method for obtaining EPO by separating the supernatant comprising EPO and insulin from mammalian cells which express recombinant human erythropoietin, concentrating said supernatant and freezing the concentrated product.

The invention provides the above and below-described methods wherein said concentration step concentrates the supernatant from about 25 to 200 fold, preferably about 50 to 150 fold, and most preferably 100 fold.

The invention provides the above and below-described methods wherein said concentration step comprises using a tangential filtration system through membranes with a molecular weight cut-off of about 3,000 Daltons.

The invention also provides a method for obtaining human erythropoietin by separating the supernatant comprising EPO and insulin from mammalian cells which express recombinant human erythropoietin, concentrating said supernatant, freezing the concentrated product and sterile filtering said concentrated product. Preferably said sterile filtering is through membranes with a pore diameter ranging from about 0.1 to about 0.2 μm , and most preferably about 0.2 μm .

The EPO protein can be further purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation,

acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography.

5 A preferred method of further purifying the EPO comprises treating cell culture supernatants comprising EPO by a combination of the following steps: (a) differential precipitation, (b) hydrophobic interaction chromatography, (c) diafiltration, (d) anionic exchange chromatography, (e) cationic exchange chromatography and (f) molecular exclusion chromatography. Preferably, said steps are performed in the following order: (a), (b), (c), (d), (e), and (f).

10 A preferred method of using the EPO produced by the culturing of the present invention comprises lyophilization into a form suitable for injection into humans for the treatment of diseases. Specifically, the preferred lyophilization procedure comprises placing the EPO into a pharmaceutical composition, loading the first EPO composition into a container, wherein said container is at a
15 temperature equal to or less than -30°C ; incubating said EPO composition at a temperature equal to or less than -30°C under atmospheric pressure for a time equal to or greater than 4 hours; exposing said composition at a pressure of equal to or less than 30 absolute microns for a time equal to or greater than one hour; and raising the temperature equal to or less than 3°C per hour until reaching at
20 least 25°C , while keeping pressure values equal to or less than 5 absolute microns.

A preferred pharmaceutical composition for lyophilization comprises EPO, sugar, salts and human albumin. An especially preferred composition for lyophilization comprises EPO, mannitol, NaCl, NaH_2PO_4 , Na_2HPO_4 and human
25 albumin.

The invention also provides a method for obtaining human erythropoietin by separating the supernatant comprising EPO and insulin from mammalian cells which express recombinant human erythropoietin, adding media comprising insulin to separated cells and culturing said cells.

30 The present invention is described in further detail in the following non-limiting examples.

Examples

Example 1 - Culture

The recombinant human EPO is produced in a mammalian cell line (CHO) transfected with human erythropoietin genomic DNA. The cell banks ("Master" and "Working Bank") containing the EPO producing cells were preserved in liquid nitrogen according to commonly used laboratory methods. See Hames et al., "Transcription and Translation. A Practical Approach", (IRL Press, Oxford, England, 1984), incorporated herein as reference. Four "seeds" from the EPO working bank were thawed and added separately to four T 25 flasks containing 10 ml of culture medium no. 1 each. See Table 1. For each T 25 flask the following protocol was applied:

The EPO producing cells were cultured for 24 hours at 37 °C. The culture medium was then removed and 10 ml of medium no. 2 were added to each T 25 flask. See Table 1. The cell cultures were preserved at the same conditions for an additional 24 hour period. The resulting EPO producing cell cultures were then subject to a series of expansion stages as described in the following examples.

Example 2 - Expansion 1

Each cell culture from Example 1 was removed from the T 25 flasks by trypsin treatment according to commonly used laboratory methods. See Hames et al., *supra*. Afterwards, the cell cultures were grown according to the following protocol: to each one of five T 25 flasks, 20 % of each grown cell culture and 10 ml of culture medium no. 2 were added. See Table 1. The EPO producing cell cultures were incubated further for 48 hours at 37 °C.

Example 3 - Expansion 2

The five cell cultures from the previous example were removed from the T 25 flasks by trypsin treatment according to commonly used laboratory methods. See Hames et al., *supra*. Each cell culture was transferred to a T 150 flask. Subsequently, 75 ml of culture medium no. 1 were added to each T 150 flask. See Table 1. The EPO producing cell cultures were then incubated for 72 hours at 37 °C.

Example 4 - Expansion 3

The cell cultures from the previous example were removed from the T 150 flasks by trypsin treatment according to commonly used laboratory methods. See Hames et al., *supra*. 10 % of the cell culture of each T 150 flask was transferred to a new T 150 flask. 75 ml of culture medium no. 1 were added to each new T 150 flask. See Table 1. The EPO producing cell cultures were then incubated for 72 hours at 37 °C.

Example 5 - Expansion 5

The cell cultures from the previous example were removed from the T 150 flasks by trypsin treatment according to commonly used laboratory methods. See Hames et al., *supra*. The cell cultures from each T 150 flask were transferred to a "roller" flask of 850 cm² of inner surface. 200 ml of culture medium no. 1 were added to each roller flask. See Table 1. The EPO producing cell cultures were then incubated for 72 hours at 37 °C.

Example 6 - Expansion 6

The cell cultures from the previous example were removed from the roller flasks by trypsin treatment according to commonly used laboratory methods. See

Hames et al., *supra*. 1/15th of each cell culture was transferred to a new roller flask. In total 3,000 roller flasks containing the EPO producing cell culture were prepared and grown according to the following protocol:

5 200 ml of culture medium no. 1 were added to each roller flask. The EPO producing cell cultures were then incubated for 72 hours at 37 °C. The roller rotation speed was 11 rounds per hour.

10 The formation of a cell monolayer was verified by an inverted microscopic analysis. The culture medium of each roller flask was discarded and the EPO producing cell cultures were rinsed with 300 ml Hank's solution per roller. See Table 1. 200 ml of culture medium no. 3 was then added to each roller flask.

Example 7 - Harvest

15 The culture supernatant of each cell culture from the preceding example was harvested every 48 hours, under strict sterile conditions, and replaced with 200 ml of fresh culture medium no. 3. This procedure was repeated 5 times for each roller flask.

20 The harvested culture supernatant was concentrated a hundred-fold with a tangential filtration system utilizing 3,000 D cut off Amicon S10Y3 membranes. The concentrated material was filtered under sterile conditions and stored at - 20 °C.

A cellular density between 180,000 cells per cm² and 800,000 cell per cm² was achieved. Cell viability ranged between 95 % and 98 % throughout the whole procedure. The harvested supernatant was 2,900 liters. The material concentrated according to example 7 yielded 29.5 liters.

The following table summarizes the results of each harvest stage:

HARVEST	EPO-RIA (g)	TOTAL PROTEINS (g)
1	26.55	51.33
2	38.05	95.87
3	37.76	100.0
4	32.45	134.8
5	33.04	161.7
TOTAL	167.85	543.7

Example 8 - EPO Assays

The EPO obtained in the previous example was further purified and assayed for identity and biological activity according to the following protocol.

In a denaturing SDS-PAGE gel EPO was identified as a wide band of molecular weight as expected for EPO. See Figure 1. The band was recognized by monoclonal and polyclonal antibodies raised against human EPO in a Western blot assay as expected for EPO. See Figure 2. The treatment with glycanases proved the existence of the glycosidic chains in the extent and size expected for EPO. See Figure 3. The EPO produced was shown to be composed of a series of species with isoelectric points ranging from 3.0 to 4.5 as expected for EPO. See Figure 4.

The complete amino acid sequence of the isolated protein, purified from the culture supernatant of transfected cell lines showed total homology with natural human erythropoietin whose 165 amino acid sequence is as follows (SEQ ID NO:1):

NH ₂ --	Ala	Pro	Pro	Arg	Leu	Ile	Cys	Asp
	Ser	Arg	Val	Leu	Glu	Arg	Tyr	Leu
	Leu	Glu	Ala	Lys	Glu	Ala	Glu	<u>Asn</u>

-12-

Ile	Thr	Thr	Gly	Cys	Ala	Glu	His
Cys	Ser	Leu	Asn	Glu	<u>Asn</u>	Ile	Thr
Val	Pro	Asp	Thr	Lys	Val	Asn	Phe
Tyr	Ala	Trp	Lys	Arg	Met	Glu	Val
Gly	Gln	Gln	Ala	Val	Glu	Val	Trp
Gln	Gly	Leu	Ala	Leu	Leu	Ser	Glu
Ala	Val	Leu	Arg	Gly	Gln	Ala	Leu
Leu	Val	<u>Asn</u>	Ser	Ser	Gln	Pro	Trp
Glu	Pro	Leu	Gln	Leu	His	Val	Asp
Lys	Ala	Val	Ser	Gly	Leu	Arg	Ser
Leu	Thr	Thr	Leu	Leu	Arg	Ala	Leu
Gly	Ala	Gln	Lys	Glu	Ala	Ile	Ser
Pro	Pro	Asp	Ala	Ala	<u>Ser</u>	Ala	Ala
Pro	Leu	Arg	Thr	Ile	Thr	Ala	Asp
Thr	Phe	Arg	Lys	Leu	Phe	Arg	Val
Tyr	Ser	Asn	Phe	Leu	Arg	Gly	Lys
Leu	Lys	Leu	Tyr	Thr	Gly	Glu	Ala
Cys	Arg	Thr	Gly	Asp	----COOH		

The presence of the four glycosylation sites on the 165 amino acid chain, as well as the complex carbohydrate structure, and in particular, the sialic acid terminal residues, which characterizes EPO were verified. These results were further supported by a biological activity assay of the produced protein by an ex-hypoxic polycythemic mice test which showed complete concordance with the international EPO standard.

After purification, 30 % of the EPO obtained was recovered. The surprisingly high protein yield ratio is attributed to the initial low level of impurities resulting from the claimed invention. The low level of impurities of the culture supernatant is due to the substitution of fetal calf serum by insulin. The insulin substitution prevents the occurrence of metabolites of animal origin in the culture supernatant.

Under the traditional culture methods, which utilize 10 % fetal calf serum, the EPO recovery is less than 1 %. The recovery ratio of the claimed method is thirty times higher than this.

* * * * *

5 All publications mentioned hereinabove are hereby incorporated in their entirety by reference.

While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can
10 be made without departing from the true scope of the invention and appended claims.

Table Number 1

Culture Medium no. 1
Basal Culture Medium + 10 % Fetal Calf Serum

15	ISCOVE'S DNEM	8.85 g/l	Tryptophan	27mg/l
	HAM F12	5.35 g/l	Asparagine	40mg/l
	NaHCO ₃	2.10 g/l	Serine	80mg/l
	Glucose	1.30 g/l	Ethanolamine	3 g/l
	Lactose	0.20 g/l	Glutamine	1.90 g/l
20	Galactose	0.20 g/l	Fetal Calf Serum	100 ml/l
	Sodium Pyruvate	0.11 g/l		

Culture Medium no. 2
Basal Culture Medium +10 % Fetal Calf Serum + Geneticin 0.5 mg/ml

5	ISCOVE'S DNEM	8.85 g/l	Tryptophan	27mg/l
	HAM F12	5.35 g/l	Asparagine	40mg/l
	NaHCO ₃	2.10 g/l	Serine	80mg/l
	Glucose	1.30 g/l	Ethanolamine	3mg/l
	Lactose	0.20 g/l	Glutamine	0.20 g/l
	Sodium Pyruvate	0.11 g/l	Fetal Calf Serum	100 ml/l
10	Glutamine	1.90 g/l	Geneticin	500 mg/l

Culture Medium no. 3
Basal Culture Medium + Insulin

15	ISCOVE'S DNEM	8.85 g/l	Tryptophan	27mg/l
	HAM F12	5.35 g/l	Asparagine	40mg/l
	NaHCO ₃	2.10 g/l	Serine	80mg/l
	Glucose	1.30 g/l	Ethanolamine	3mg/l
	Lactose	0.20 g/l	Glutamine	0.20 mg/l
	Galactose	0.20 g/l	Sodium Pyruvate	0.11 g/l
	Glutamine	1.90 g/l	Insulin	10 mg/l

20

HANK's Solution

CaCl ₂ •2H ₂ O	185 mg/l	Glucose	1.0 g/l
MgSO ₄ •7 H ₂ O	140 mg/l	NaHCO ₃	350 mg/l
KCl	400 mg/l	KH ₂ PO ₄	60 mg/l
NaCl	8.0 g/l	Na ₂ HPO ₄	47.8 mg/l

What Is Claimed Is:

1. A method for obtaining human erythropoietin comprising (a) culturing mammalian cells which express recombinant human erythropoietin in culture medium comprising insulin.
- 5 2. The method of claim 1, wherein said cells are selected from the group comprising CHO, COS, BHK, Namalwa, and HeLa.
3. The method of claim 2, wherein said cells comprise CHO cells.
4. The method of claim 1, wherein said culture medium comprises greater than 1 mg insulin per liter of culture medium.
- 10 5. The method of claim 1, wherein said culture medium comprises less than 20 mg insulin per liter of culture medium.
6. The method of claim 1, wherein said culture medium comprises fetal calf serum-free media.
7. The method of claim 1, further comprising:
 - 15 (b) separating supernatant comprising EPO and insulin from step (a) from cells;
 - (c) concentrating supernatant of step (b); and
 - (d) freezing concentrated product of step (c).
8. The method of claim 7, wherein media is added to separated cells
20 of step (b) and said cells are cultured.
9. The method of claim 7, wherein supernatant of said step (b) is concentrated approximately 50 to 150 fold.

10. The method of claim 7, wherein supernatant of said step (b) is concentrated about 100 fold.

11. The method of claim 7, wherein said step (c) comprises using a tangential filtration system through membranes with a molecular weight cut-off of about 3,000 Daltons.

5

12. The method of claim 7, further comprising (e) sterile filtering the concentrated product of step (d) through membranes with pores of diameters of about 0.2 mm.

Fig. 3. SDS-PAGE analysis of EPO digestion with glycanases




Fig. 4. Determination of isoelectric point (isoelectric focusing)




Fig. 1. Polyacrylamide gel electrophoresis (SDS-PAGE)





Fig. 2. Western blot analysis



-1-

SEQUENCE LISTING

<110> Sterrenbeld Biotechnologie North America, Inc.

Carcagno, Carlos Miguel

Criscuolo, Marcelo

Melo, Carlos

Vidal, Juan Alejandro

<120> Method for the Massive Culture of Cells Producing Recombinant Human Erythropoietin

<130> 1792.004PC02

<140>

<141>

<150> AR 99-01-00681

<151> 1999-02-23

<150> AR 98-01-05611

<151> 1998-11-06

<160> 1

<170> PatentIn Ver. 2.0

<210> 1

<211> 165

<212> PRT

<213> Homo sapiens

<400> 1

Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu

1

5

10

15

Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His

20

25

30

Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe

35

40

45

WO 00/27997

-2-

Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp
 50 55 60

Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu
 65 70 75 80

Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp
 85 90 95

Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu
 100 105 110

Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala
 115 120 125

Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val
 130 135 140

Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala
 145 150 155 160

Cys Arg Thr Gly Asp
 165

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/26240

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 5/00, 5/02; A01N 63/00; A01N 1/02

US CL : 435/325, 405, 1.1; 424/93.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/325, 405, 1.1; 424/93.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN, WEST

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JIXIAN, D. et al. Serum-free medium used for the production of rHuEPO. Junshi Yixue Kexueyuan Yuankan. 1997, Vol. 21, No. 4, pages 244-246, see English abstract.	1-12



Further documents are listed in the continuation of Box C.



See patent family annex.

*

Special categories of cited documents:

T

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

A

document defining the general state of the art which is not considered to be of particular relevance

X

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

B

earlier document published on or after the international filing date

Y

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

L

document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O

document referring to an oral disclosure, use, exhibition or other means

P

document published prior to the international filing date but later than the priority date claimed

A

document member of the same patent family

Date of the actual completion of the international search

21 JANUARY 2000

Date of mailing of the international search report

22 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

YVETTE S. CONNELL

Telephone No. (703) 308-0196